Virtu KCG Holdings’s Moleculin Biotech MBRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
$676K Buy
8
+3
+60% +$131K 0.02% 875
2017
Q1
$274K Buy
+5
New +$350K 0.01% 2049
2016
Q4
– Hold
0
– -$66K – 3644
2016
Q3
– Hold
0
– – – 2735

Other funds holding MBRX

Virtu KCG Holdings's MBRX Position: Q2 2017 in Review

Virtu KCG Holdings increased its Moleculin Biotech (MBRX) stake by 60% in Q2 2017, buying an estimated $131K and bringing the position to 8 shares worth $676K. The position accounts for 0.02% of the portfolio, ranked #875.

Virtu KCG Holdings first reported a position in MBRX in Q1 2017 and has held it in 2 quarters since. 7 funds tracked by Wall St. Rank hold MBRX as of Q2 2017.

  • Virtu KCG Holdings held 8 shares of Moleculin Biotech worth $676K as of Q2 2017.
  • Virtu KCG Holdings bought 3 Moleculin Biotech shares in Q2 2017, an estimated $131K.
  • Moleculin Biotech made up 0.02% of Virtu KCG Holdings's portfolio in Q2 2017, its #875 holding.
  • Virtu KCG Holdings first reported a position in Moleculin Biotech in Q1 2017 and has held it in 2 quarters since.
  • 7 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.